BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 25148533)

  • 1. Experimentally validated HERG pharmacophore models as cardiotoxicity prediction tools.
    Kratz JM; Schuster D; Edtbauer M; Saxena P; Mair CE; Kirchebner J; Matuszczak B; Baburin I; Hering S; Rollinger JM
    J Chem Inf Model; 2014 Oct; 54(10):2887-901. PubMed ID: 25148533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamics of hERG closure allow novel insights into hERG blocking by small molecules.
    Schmidtke P; Ciantar M; Theret I; Ducrot P
    J Chem Inf Model; 2014 Aug; 54(8):2320-33. PubMed ID: 25000969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A ligand-based virtual screening approach to identify small molecules as HERG channel activators.
    Giacomini E; Buonfiglio R; Masetti M; Wang Y; Tseng GN; Roberti M; Recanatini M
    Comb Chem High Throughput Screen; 2015; 18(3):269-80. PubMed ID: 25747449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Electrophysiological analysis of mammalian cells expressing hERG using automated 384-well-patch-clamp.
    Haraguchi Y; Ohtsuki A; Oka T; Shimizu T
    BMC Pharmacol Toxicol; 2015 Dec; 16():39. PubMed ID: 26671227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. hERG drug response measured in droplet bilayers.
    Portonovo SA; Salazar CS; Schmidt JJ
    Biomed Microdevices; 2013 Apr; 15(2):255-9. PubMed ID: 23160842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A human ether-á-go-go-related (hERG) ion channel atomistic model generated by long supercomputer molecular dynamics simulations and its use in predicting drug cardiotoxicity.
    Anwar-Mohamed A; Barakat KH; Bhat R; Noskov SY; Tyrrell DL; Tuszynski JA; Houghton M
    Toxicol Lett; 2014 Nov; 230(3):382-92. PubMed ID: 25127758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In silico prediction of the chemical block of human ether-a-go-go-related gene (hERG) K+ current.
    Inanobe A; Kamiya N; Murakami S; Fukunishi Y; Nakamura H; Kurachi Y
    J Physiol Sci; 2008 Dec; 58(7):459-70. PubMed ID: 19032804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Global analysis reveals families of chemical motifs enriched for HERG inhibitors.
    Du F; Babcock JJ; Yu H; Zou B; Li M
    PLoS One; 2015; 10(2):e0118324. PubMed ID: 25700001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Common pharmacophores for uncharged human ether-a-go-go-related gene (hERG) blockers.
    Aronov AM
    J Med Chem; 2006 Nov; 49(23):6917-21. PubMed ID: 17154521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining structure- and ligand-based approaches for studies of interactions between different conformations of the hERG K+ channel pore and known ligands.
    Coi A; Bianucci AM
    J Mol Graph Model; 2013 Nov; 46():93-104. PubMed ID: 24185260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective validation of a comprehensive in silico hERG model and its applications to commercial compound and drug databases.
    Doddareddy MR; Klaasse EC; Shagufta ; Ijzerman AP; Bender A
    ChemMedChem; 2010 May; 5(5):716-29. PubMed ID: 20349498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Halide ion effects on human Ether-à-go-go related gene potassium channel properties.
    Zeng H; Balasubramanian B; Penniman JR; Kinose F; Salata JJ; Lagrutta A
    Assay Drug Dev Technol; 2013; 11(9-10):544-50. PubMed ID: 24147984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of human Ether-à-go-go related gene screening assays based on IonWorks Quattro and thallium flux.
    Bridal TR; Margulis M; Wang X; Donio M; Sorota S
    Assay Drug Dev Technol; 2010 Dec; 8(6):755-65. PubMed ID: 20658944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of Safe Drugs: The hERG Challenge.
    Kalyaanamoorthy S; Barakat KH
    Med Res Rev; 2018 Mar; 38(2):525-555. PubMed ID: 28467598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent developments in computational prediction of HERG blockage.
    Wang S; Li Y; Xu L; Li D; Hou T
    Curr Top Med Chem; 2013; 13(11):1317-26. PubMed ID: 23675938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural analysis of hERG channel blockers and the implications for drug design.
    AlRawashdeh S; Chandrasekaran S; Barakat KH
    J Mol Graph Model; 2023 May; 120():108405. PubMed ID: 36680816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-activity relationships of pentamidine-affected ion channel trafficking and dofetilide mediated rescue.
    Varkevisser R; Houtman MJ; Linder T; de Git KC; Beekman HD; Tidwell RR; Ijzerman AP; Stary-Weinzinger A; Vos MA; van der Heyden MA
    Br J Pharmacol; 2013 Jul; 169(6):1322-34. PubMed ID: 23586323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multiscale simulation system for the prediction of drug-induced cardiotoxicity.
    Obiol-Pardo C; Gomis-Tena J; Sanz F; Saiz J; Pastor M
    J Chem Inf Model; 2011 Feb; 51(2):483-92. PubMed ID: 21250697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a high-throughput electrophysiological assay for the human ether-à-go-go related potassium channel hERG.
    Gillie DJ; Novick SJ; Donovan BT; Payne LA; Townsend C
    J Pharmacol Toxicol Methods; 2013; 67(1):33-44. PubMed ID: 23103595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blockade of human HERG K⁺ channels by rosiglitazone, an antidiabetic drug.
    Lee SH; Sung MJ; Hahn SJ; Kim J; Min G; Jo SH; Choe H; Choi BH
    Arch Pharm Res; 2012 Sep; 35(9):1655-64. PubMed ID: 23054723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.